Seelos Therapeutics Inc. Stock
Seelos Therapeutics Inc. Stock
Pros and Cons of Seelos Therapeutics Inc. in the next few years
Pros
Cons
Performance of Seelos Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Seelos Therapeutics Inc. | - | - | - | - | - | - | - |
| Beximco Pharmaceuticals Ltd. GDR | 0.940% | -4.444% | -1.376% | -4.444% | -2.273% | -51.136% | -23.214% |
| Cellectar BioSciences Inc. | 2.820% | -1.389% | -23.656% | 102.857% | 24.561% | -77.097% | - |
| SELLAS Life Sciences Group Inc | -15.740% | -5.028% | 45.923% | 3.343% | 39.487% | -80.571% | -99.630% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Seelos Therapeutics, operating under the US symbol APRI, has shown a fluctuating financial performance in recent years. The financial statements of the company exhibit some strong points, such as an influx of capital stock, increased research and development expenses, and a considerable amount of cash on hand. However, they also reveal some areas of concern, including negative stockholder equity, declining net income, and mounting liabilities. Overall, the financials of Seelos Therapeutics present a mixed picture requiring a deeper analysis of the pros and cons.
Rising research and development (R&D) expenses: An increasing trend in R&D spending is usually a positive sign for a pharmaceutical firm, as it signifies investments in new drug developments and innovations. Seelos Therapeutics' continuous growth in R&D expenses over the years, with a significant rise from $10.98 million in 2020 to $58.62 million in 2022, demonstrates the company's dedication to discovering effective drugs and therapies.
Increased capital stock issuance: The issuance of additional capital stocks, reaching a peak of $118.16 million in 2021, helped to raise funds necessary for financing the firm's operations and expansion plans. This additional capital signals the confidence of investors in the company's potential for future growth.